The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529

Leukemia Research

Volumn 29, Issue 4, 2005, Pages 451-457

  Segawa, Hidekazu ^a,b   Kimura, Shinya ^a   Kuroda, Junya ^a   Sato, Kiyoshi ^a   Nogawa, Masaki ^a   Yuasa, Takeshi ^a   Yokota, Asumi ^a   Hodohara, Keiko ^b   Fujiyama, Yoshihide ^b   Maekawa, Taira ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Apoptosis; Bisphosphonate; Leukemia; Ras proteins; YM529

Indexed keywords

CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P; MINODRONIC ACID; PACLITAXEL; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL;

EID: 13844267632     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.10.004     Document Type: Article

References (30)

1. L. Widler, K.A. Jaeggi, M. Glatt, K. Muller, R. Bachmann, and M. Bisping Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa) J Med Chem 45 2002 3721 3738
2. S. Suri, J. Monkkonen, M. Taskinen, J. Pesonen, M.A. Blank, and R.J. Phipps Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity Bone 29 2001 336 343
3. T. Chen, J. Berenson, R. Vescio, R. Swift, A. Gilchick, and S. Goodin Pharmacokinetics and pharmacodynatnics of zoledronic acid in cancer patients with bone metastases J Clin Pharmacol 42 2002 1228 1236
4. M. Sato, W. Grasser, N. Endo, R. Akins, H. Simmons, and D.D. Thompson Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure J Clin Invest 88 1991 2095 2105
5. J.R. Green Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies Semin Oncol 28 2001 4 10
6. H.L. Neville-Webbe, I. Holen, and R.E. Coleman The anti-tumour activity of bisphosphonates Cancer Treat Rev 28 2002 305 319
7. S.P. Jagdev, R.E. Coleman, C.M. Shipman, H.A. Rostami, and P.L. Croucher The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel Br J Cancer 84 2001 1126 1134
8. T. Hiraga, P.J. Williams, G.R. Mundy, and T. Yoneda The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases Cancer Res 61 2001 4418 4424
9. M.V. Lee, E.M. Fong, F.R. Singer, and R.S. Guenette Bisphosphonate treatment inhibits the growth of prostate cancer cells Cancer Res 61 2001 2602 2608
10. S.S. Virtanen, H.K. Vaananen, P.L. Harkonen, and P.T. Lakkakorpi Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway Cancer Res 62 2002 2708 2714
11. P. Tassone, S. Forciniti, E. Galea, G. Morrone, M.C. Turco, and V. Martinelli Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines Leukemia 14 2000 841 844
12. R. Takahashi, C. Shimazaki, T. Inaba, A. Okano, M. Hatsuse, and A. Okamoto A newly bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells Leukemia Res 25 2001 77 83
13. + leukemia activity of imatinib mesylate Blood 102 2003 2229 2235
14. Y. Urasaki, T. Ueda, A. Yoshida, T. Fukushima, N. Takeuchi, and T. Tsuruo Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms Anticancer Res 16 1996 709 714
15. S. Kimura, T. Maekawa, K. Hirakawa, A. Murakami, and T. Abe Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells Cancer Res 55 1995 1379 1384
16. S. Matsumoto, S. Kimura, H. Segawa, J. Kuroda, T. Yuasa, and K. Sato Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines Lung Cancer 47 2005 31 39
17. S. Kimura, J. Kuroda, H. Segawa, K. Sato, M. Nogawa, and T. Yuasa Anti-proliferative efficacy of the third generation bisphosphonate zoledronic acid, combined with other anti-cancer drugs in leukemk cell lines Int J Hematol 79 2004 37 43
18. K.U. Chow, J. Ries, E. Weidmann, F. Pourebrahim, S. Napieralski, and M. Stieler Induction of apoptosis using 2′,2′ difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeiokl cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells Ann Hematol 79 2000 485 492
19. H.M. McDaid, and P.G. Johnston Synergistic interaction between paclitaxel and 8-chloro-adenosine 3′,5′-monophosphate in human ovarian carcinoma cell lines Clin Cancer Res 5 1999 215 220
20. A.A. Reszka, J. Halasy-Nagy, and G.A. Rodan Nitrogen-bisphosphonales block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation Mol Pharmacol 59 2001 193 202
21. A.G. Turhan, E. Solary, W. Vainchenker, and I. Dusanter-Fourt Molecular pathophysiology of chronic myelogeneous leukemia Hematol Cell Ther 40 1998 217 221
22. A. Neri, D.M. Knowles, A. Greco, F. McCormick, and R. Dalla-Favera Analysis of RAS oncogene mutations in human lymphoid malignancies Proc Natl Acad Sci USA 85 1988 9268 9272
23. bcr-abl Oncogene 22 2003 6445 6454
24. D. Ishida, K. Kometani, H. Yang, K. Kakugawa, K. Masuda, and K. Iwai Myeloproliferative stem ceil disorders by deregulated Rap1 activation in SPA-1-deficient mice Cancer Cell 4 2003 55 65
25. D.G. Peters, R.R. Hoover, M.J. Gerlach, E.Y. Koh, H. Zhang, and K. Choe Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia Blood 97 2001 1404 1412
26. J. Cortes, M. Albitar, D. Thomas, F. Giles, R. Kurzrock, and A. Thibault Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies Blood 101 2003 1692 1697
27. M.A. Morgan, J. Wegner, E. Aydilek, A. Ganser, and CW.M. Reuter Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors Leukemia 17 2003 1508 1520
28. D.E. Colburn, D.A. Thomas, and F.J. Giles Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia Invest New Drug 21 2003 109 111
29. R. Munker, H. Kantarjian, S. O'Brien, M. Keating, M. Andreeff, and E.H. Estey Phase I study of taxol in refractory acute myelogeneous leukemias using a weekly schedule Acta Haematol 99 1998 106 108
30. Center for Drug Evaluation and Research. Approval Page. Zometa (zoledronic acid) Injection. Pharmacology Review (s). Part 2 p. 84. Pharmacokinetics Summary http://www.fda.gov/cder/foi/nda/2001/21-223_Zometa.htm.